FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Morris Jeffrey Allen		 2. Date of Event Requiring Statement (MM/DD/YYYY)
3/27/2023 

 3. Issuer Name and Ticker or Trading Symbol

PROVECTUS BIOPHARMACEUTICALS, INC. [PVCT]
(Last)        (First)        (Middle)

1729 TRIANGLE PARK DRIVE		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          ___X___ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

MARYVILLE, TN 37801      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 18500000 (1)D  
Series D-1 Convertible Preferred Stock 3806990 (2)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
8% Secured Convertible Promissory Note 5/5/2023 5/5/2023 Series D-1 Convertible Preferred Stock $500000 (3)$2.862 D  
Explanation of Responses:
(1) The reporting person has sole voting and dispositve power over 12,000,000 shares of Common Stock, plus 6,500,000 shares of Common Stock owned through a retirement plan.
(2) The reporting person has sole voting and dispositve power over 3,806,990 shares of Series D-1 Convertible Preferred Stock, convertible into 38,069,900 shares of Common Stock.
(3) The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share on 05/05/2023.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Morris Jeffrey Allen
1729 TRIANGLE PARK DRIVE
MARYVILLE, TN 37801
X
Signatures
/s/ Jeffrey Allen Morris3/27/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas Provectus Biopharmaceuti... (QB).
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas Provectus Biopharmaceuti... (QB).